title: The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
abstract: To assess the effects of deferoxamine (DFO) on the kidneys, we studied 27 patients with thalassemia major on chronic subcutaneous (s.c.) DFO therapy. In 41% of the patients glomerular filtration rate (GFR) values were above the normal range. In a previous study similar findings were reported for thalassemia patients who did not receive DFO. The subcutaneous administration of DFO was associated with a clinically significant decrease in GFR in 40% of the patients and in a mild decrease in another 40%. In all cases of severe decreases in GFR, it tended to return to baseline values upon discontinuation of DFO. There was a significant increase in urine volume during DFO therapy. These changes are consistent with our previous observation in humans and dogs receiving high dose i.v. DFO, albeit milder.
authors.affiliation: Division of Clinical Pharmacology, Hospital for Sick Children, Toronto, Canada.
authors.forename: G
authors.initials: G
authors.lastname: Koren
authors.forename: Y
authors.initials: Y
authors.lastname: Kochavi-Atiya
authors.forename: Y
authors.initials: Y
authors.lastname: Bentur
authors.forename: N F
authors.initials: NF
authors.lastname: Olivieri
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007279:Injections, Subcutaneous; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D013789:Thalassemia / Q000188:drug therapy*
chemical_list: D003676:Deferoxamine